Intrathecal Pump RefillIMPROVENCT07727798
Intrathecal Pump Refills at Home or at the Hospital
A study testing Refill at the hospital and Refill at home in people with Intrathecal Pump Refill, run by Moens Maarten at 1 site in Belgium.
Trial summary
The IMPROVE study is a randomized, controlled, cross-over trial designed to compare intrathecal pump refills performed at home with those carried out in the hospital. Intrathecal drug delivery (IDD) is used in patients with chronic pain or severe spasticity. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Intrathecal Pump Refill
- What is being tested?
- Refill at the hospital and Refill at home
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 82 participants
- Where
- 1 siteBelgium
- Study dates
- 15 Oct 2025to 1 Oct 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Actively receiving Intrathecal drug delivery
- Stable medication dosage for at least 3 months
- Dutch, French or English speaking adults
Who cannot join
- Life expectancy < 6 months
- Patients planned for but not yet received Intrathecal drug delivery implant
- No residence in Belgium
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
UZ Brussel
Jette, 1090
Maarten Moens, MD PhD
Ulrike Van Hoey, MSc
About this study
Official title: Intrathecal Pump Refills at Home or at the Hospital: a Randomized Controlled Crossover Trial
The IMPROVE study is a randomized, controlled, cross-over trial designed to compare intrathecal pump refills performed at home with those carried out in the hospital. Intrathecal drug delivery (IDD) is used in patients with chronic pain or severe spasticity. Use of IDD requires the performance of pump refills about 4-6 times a year which may be a burdensome and stressful experience for patients and their caregivers. Hospital visits can increase stress, pain, and caregiver strain, while early pilot studies suggest home-based refills may be both safe and more comfortable.
Eighty-two adult patients in Belgium with an implanted intrathecal pump will be enrolled in the IMPROVE study. Each participant will undergo four refill procedures: two at home and two at the hospital, in randomized order.
- Conditions
- Intrathecal Pump Refill
- Being tested
- Refill at the hospital, Refill at home
- Keywords
- Intrathecal drug delivery, intrathecal pump therapy, neuromodulation, refill, patient comfort, telemedicine, remote care, hospital to home transition
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Refill at the hospitalProcedure or surgery
Intrathecal pump refill procedure conducted at the hospital
Refill at homeProcedure or surgery
Intrathecal pump refill procedure conducted at the home of the patient
| Study group | Role | What they receive |
|---|---|---|
| Refill at home | Active comparator | Not described Receives: Procedure: Refill at home |
| Refill at the hospital | Active comparator | Not described Receives: Procedure: Refill at the hospital |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Comfort
Patient comfort is evaluated with the General Comfort Questionnaire (GCQ), a self-reported instrument consisting of 48 items that reflect the physical, spiritual, environmental and social dimension. Responses are rated on a four-point Likert scale ranging from "strongly disagree" to "strongly agree". Some items are reverse scored during data processing, with higher overall scores indicating greater levels of comfort.
Measured: At baseline and immediately after each intervention.
Secondary outcomes (15)
Quality of life
The McGill Quality of Life Questionnaire (MQOL) will measure quality of life and consists of 17 questions. Higher scores reflect a better quality of life.
Measured: At baseline and immediately after each intervention.
Health-related quality of life
The EuroQol with five dimensions and five levels (EQ-5D-5L) will be assessed to measure health-related quality of life. Higher scores reflect a better quality of life.
Measured: At baseline and immediately after each intervention.
Pain intensity
The Visual Analogue Scale (VAS - 100 mm) in electronic format will be used for the assessment of current pain intensity.
Measured: At baseline and immediately after each intervention.
Pain interference
The NIH-funded Patient-Reported Outcomes Measurement Information System Pain Interference measure assesses the impact of pain on key aspects of an individual's life. It evaluates the extent to which pain disrupts engagement in social, cognitive, emotional, physical, and recreational activities.
Measured: At baseline and immediately after each intervention.
Stress
Saliva samples will be collected to measure cortisol levels with synthetic salivettes.
Measured: 5 minutes before the refill, immediately after the refill and 10 minutes after the refill procedure.
Anxiety
Patient anxiety will be assessed through the State Trait Anxiety Inventory (STAI). This questionnaire consists of 40 Likert-type items on a four-point scale. Higher scores are indicating higher levels of anxiety.
Measured: At baseline and immediately after each intervention.
Self-efficacy
The General Self-Efficacy (GSE) Scale is a 10-item self-report questionnaire used to assess perceived self-efficacy.
Measured: At baseline and immediately after each intervention.
Caregiver burden
To evaluate caregiver burden, the Zarit Burden Interview (ZBI) questionnaire will be completed. This 12-item self-report instrument assesses caregiver burden and is a shortened version of the original 22-item Zarit Burden Scale. The total score ranges from 0 to 48, with higher totals reflecting more significant caregiver burden.
Measured: At baseline and immediately after each intervention.
Patient satisfaction
Patient satisfaction is evaluated with a seven-point Likert scale asking the patient to rate the overall level of satisfaction with the refill at home.
Measured: Immediately after each refill procedure at home (intervention).
Tele-monitoring quality
The quality of tele-monitoring will only be evaluated after a home-filling. This will be examined using three different Likert scales to score 1) quality of audio, 2) quality of video, and 3) overall quality of the teleconsultation.
Measured: Immediately after each refill procedure at home (intervention).
Duration of refill
The time required for the full procedure will be recorded.
Measured: Immediately after each intervention.
Safety of the refill procedure at home
Patients will evaluate the overall safety of the procedure using a seven-point Likert scale. In addition, the researcher will assess safety on three levels: (1) overall perceived safety of the procedure using a seven-point Likert scale; (2) environmental safety, assessed through an open-ended question addressing any situations perceived as unsafe; and (3) the ability to perform the procedure in a clean and sterile manner, also evaluated via an open-ended question.
Measured: Immediately after each refill procedure at home (intervention).
Health expenditure
Expenditures related to in hospital care will be extracted from hospital claims data. All other healthcare-related costs will be gathered through telephone interviews with patients, conducted four weeks after the first and second medication refills. During these calls, researchers will ask patients whether they have had any medical consultations, hospital admissions, adverse events, changes in medication, or incurred any additional healthcare costs.
Measured: Four weeks after the first and second intervention.
Patient preference
After the fourth refill procedure, patients will be asked to indicate their preference (refill at home, refill in the hospital, no preference or other) for the location of their refills in the future.
Measured: Immediately after the final study intervention
Discrete choice experiment
After the fourth refill procedure, patients will be presented with a discrete choice experiment to evaluate their preferences across several scenarios.
Measured: Immediately after the final study intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jul 2026
- Study start15 Oct 2025
- Primary completion1 Oct 2028 (estimated)
- Study completion1 Oct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intrathecal Pump RefillStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 82 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Moens Maarten
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Moens Maarten, Universitair Ziekenhuis Brussel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07727798
- Sponsor's protocol ID
- 25242_IMPROVE
- Acronym
- IMPROVE
- Status last verified
- Jul 2026
- First submitted
- 29 Sep 2025
- Last updated
- 27 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intrathecal Pump Refills at Home or at the Hospital: a Randomized Controlled Crossover Trial
- ClinicalTrials.gov ID
- NCT07727798
- Acronym / sponsor ID
- IMPROVE / 25242_IMPROVE
- Conditions
- Intrathecal Pump Refill
- Keywords
- Intrathecal drug delivery, intrathecal pump therapy, neuromodulation, refill, patient comfort, telemedicine, remote care, hospital to home transition
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 82 participants (estimated)
- Lead sponsor
- Moens MaartenUniversity, hospital or other
- Study start
- 15 Oct 2025 (actual)
- Primary completion
- 1 Oct 2028 (estimated)
- Study completion
- 1 Oct 2028 (estimated)
- First posted
- 27 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The IMPROVE study is a randomized, controlled, cross-over trial designed to compare intrathecal pump refills performed at home with those carried out in the hospital. Intrathecal drug delivery (IDD) is used in patients with chronic pain or severe spasticity. Use of IDD requires the performance of pump refills about 4-6 times a year which may be a burdensome and stressful experience for patients and their caregivers. Hospital visits can increase stress, pain, and caregiver strain, while early pilot studies suggest home-based refills may be both safe and more comfortable.
Eighty-two adult patients in Belgium with an implanted intrathecal pump will be enrolled in the IMPROVE study. Each participant will undergo four refill procedures: two at home and two at the hospital, in randomized order.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Refill at home | Active comparator | Procedure: Refill at home |
| Refill at the hospital | Active comparator | Procedure: Refill at the hospital |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Actively receiving Intrathecal drug delivery
- Stable medication dosage for at least 3 months
- Dutch, French or English speaking adults
Key exclusion criteria (3 listed)
- Life expectancy < 6 months
- Patients planned for but not yet received Intrathecal drug delivery implant
- No residence in Belgium
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Refill at the hospitalIntrathecal pump refill procedure conducted at the hospital | Procedure or surgery | Refill at the hospital |
| Refill at homeIntrathecal pump refill procedure conducted at the home of the patient | Procedure or surgery | Refill at home |
Primary outcome
Patient Comfort
Time frame: At baseline and immediately after each intervention.
Patient comfort is evaluated with the General Comfort Questionnaire (GCQ), a self-reported instrument consisting of 48 items that reflect the physical, spiritual, environmental and social dimension. Responses are rated on a four-point Likert scale ranging from "strongly disagree" to "strongly agree". Some items are reverse scored during data processing, with higher overall scores indicating greater levels of comfort.
15 secondary outcomes
Quality of life
Time frame: At baseline and immediately after each intervention.
Health-related quality of life
Time frame: At baseline and immediately after each intervention.
Pain intensity
Time frame: At baseline and immediately after each intervention.
Pain interference
Time frame: At baseline and immediately after each intervention.
Stress
Time frame: 5 minutes before the refill, immediately after the refill and 10 minutes after the refill procedure.
Anxiety
Time frame: At baseline and immediately after each intervention.
Self-efficacy
Time frame: At baseline and immediately after each intervention.
Caregiver burden
Time frame: At baseline and immediately after each intervention.
Patient satisfaction
Time frame: Immediately after each refill procedure at home (intervention).
Tele-monitoring quality
Time frame: Immediately after each refill procedure at home (intervention).
Duration of refill
Time frame: Immediately after each intervention.
Safety of the refill procedure at home
Time frame: Immediately after each refill procedure at home (intervention).
Health expenditure
Time frame: Four weeks after the first and second intervention.
Patient preference
Time frame: Immediately after the final study intervention
Discrete choice experiment
Time frame: Immediately after the final study intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jul 2026.
Related trials for Intrathecal Pump Refill
Not yet recruiting
Simulation-Based Intrathecal Pump Refill Training
Intrathecal Drug Delivery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Refill at the hospital and Refill at home in people with Intrathecal Pump Refill, run by Moens Maarten at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maarten Moens, MD PhD (+3224775514, stimulusresearchgroup@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Comfort (time frame: At baseline and immediately after each intervention.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2026.